Table 2 The comparison of 24 months survival and cyclin D1 expression in selected groups of patients.
From: Galectin-3 and cyclin D1 expression in non-small cell lung cancer
Survival | Positive Cyclin D1 expression n (%) | Negative Cyclin D1 expression n (%) | Chi2 Yatesa | p | Cox Mantel |
|---|---|---|---|---|---|
All examinated patients with NSCLC | |||||
< 24 months | 16 (41.03%) | 4 (50%) | 0.01 | 0.940 | 0.624 |
≥ 24 months | 23 (58.97%) | 4 (50%) | |||
The patients with squamous cell carcinoma | |||||
< 24 months | 8 (38.10%) | 2 (66.67%) | 0.10 | 0.754 | 0.234 |
≥ 24 months | 13 (61.90%) | 1 (33.33%) | |||
The patients with adenocarcinoma | |||||
< 24 months | 7 (58.33%) | 1 (33.33%) | 0.02 | 0.897 | 0.396 |
≥ 24 months | 5 (41.67%) | 2 (66.67%) | |||
Stage II | |||||
< 24 months | 4 (100%) | 1 (25%) | 2.13 | 0.144 | 0.076 |
≥ 24 months | 0 (0%) | 3 (75%) | |||
Stage III | |||||
< 24 months | 6 (42.86%) | 1 (50%) | 0.33 | 0.567 | 0.544 |
≥ 24 months | 8 (57.14%) | 1 (50%) | |||
Stage IV | |||||
< 24 months | 3 (75%) | 2 (100%) | 0.15 | 0.698 | 0.085 |
≥ 24 months | 1 (25%) | 0 (0%) | |||